Financial reports
10-K
2023 FY
Annual report
18 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
5 May 23
10-K
2022 FY
Annual report
20 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
10-K
2021 FY
Annual report
10 Mar 22
Current reports
8-K
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
18 Mar 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
8-K
Entry into a Material Definitive Agreement
24 Nov 23
8-K
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
8 Nov 23
8-K
Other Events
20 Oct 23
8-K
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
8-K
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
9 May 23
8-K
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
20 Mar 23
8-K
Departure of Directors or Certain Officers
18 Jan 23
Registration and prospectus
S-3
Shelf registration
2 Jul 21
424B4
Prospectus supplement with pricing info
15 Jan 21
S-1MEF
Registration of additional securities for an S-1
15 Jan 21
FWP
Free writing prospectus
11 Jan 21
S-1
IPO registration
8 Jan 21
DRS
Draft registration statement
16 Dec 20
DRSLTR
Correspondence regarding draft registration statement
15 Dec 20
424B4
Prospectus supplement with pricing info
12 Jun 20
S-1MEF
Registration of additional securities for an S-1
12 Jun 20
8-A12B
Registration of securities on exchange
8 Jun 20
Other
EFFECT
Notice of effectiveness
13 Jul 21
CORRESP
Correspondence with SEC
8 Jul 21
UPLOAD
Letter from SEC
7 Jul 21
EFFECT
Notice of effectiveness
15 Jan 21
CORRESP
Correspondence with SEC
11 Jan 21
CORRESP
Correspondence with SEC
8 Jan 21
UPLOAD
Letter from SEC
21 Dec 20
SEC STAFF LETTER
SEC staff letter
16 Jun 20
EFFECT
Notice of effectiveness
11 Jun 20
CERT
Certification of approval for exchange listing
8 Jun 20
Ownership
144
Notice of proposed sale of securities
26 Apr 24
144
Notice of proposed sale of securities
26 Apr 24
144
Notice of proposed sale of securities
26 Apr 24
144
Notice of proposed sale of securities
26 Apr 24
144
Notice of proposed sale of securities
26 Apr 24
SC 13D/A
Bios Equity Partners, LP
1 Mar 24
4
Aaron G.L. Fletcher
29 Feb 24
4
Leslie W. Kreis
29 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24